Menopause-associated changes in blood protein levels map closely to accelerated biological aging across multiple organ systems and a higher risk of later Alzheimer’s disease dementia, according to a study published in Nature Medicine in 2026. Researchers led by Alexander M. Wood tracked nearly 15,000 women across multiple cohorts, revealing that molecular shifts during the menopausal transition relate more strongly to hormonal fluctuations than to chronological age.
Proteomic Changes Across the Menopausal Transition
To investigate the biological effects of menopause, the research team initially analyzed blood serum samples from 80 women aged 43 to 58 years old. This initial cohort comprised 30 premenopausal, 26 perimenopausal, and 24 postmenopausal participants. Using an ultrasensitive protein analysis technique known as NULISAseq, investigators measured 127 proteins in the initial cohort’s central nervous system panel.
The analysis identified 16 specific proteins that showed elevated concentrations in postmenopausal women compared with premenopausal participants. These proteins are associated with immune responses, synaptic function, metabolism, and biological processes implicated in Alzheimer’s disease. Investigators synthesized these markers into a menopause-related proteomic score that climbed progressively as women moved through the transition phases. Higher scores tracked reliably with lower oestradiol concentrations and elevated follicle-stimulating hormone (FSH) levels, both measured via liquid chromatography mass-spectrometry and chemiluminescent immunoassay at the Brigham and Women’s Hospital Research Assay Core. When evaluated side by side, hormone concentrations showed a stronger relationship with these protein alterations than chronological age.
Accelerated Biological Aging Across Organ Systems
To test whether these initial signals extended to broader physiological systems, the researchers evaluated protein profiles from 2,814 age-matched women in the UK Biobank, which operates under approvals from the North West Multicentre Research Ethics Committee. Out of 2,923 proteins assessed in that broader population, 1,300 differed significantly according to menopausal status, with most showing higher concentrations post-menopause.
Among 2,340 women evaluated using protein-based aging measures, postmenopausal participants displayed less favorable biological age estimates across 11 of 13 tested organs and 36 of 38 distinct cell types when compared against premenopausal or perimenopausal peers of similar ages. These organ systems included the brain, pointing to systemic molecular shifts that outpace normal chronological aging during midlife reproductive transitions.
Associations With Cognitive Decline and Dementia Risk
Building on the biological aging data, researchers examined whether menopause-related protein signatures correlate with cognitive health outcomes in four independent cohorts of older women totaling 11,925 participants.
Higher proteomic scores consistently aligned with less favorable cognitive outcomes and faster cognitive decline across two longitudinal cohorts. In a separate UK Biobank analysis of 11,059 women tracked for approximately 15.7 years, elevated menopause-related protein scores correlated with a 15% increased hazard of developing Alzheimer's disease dementia. However, investigators did not observe statistically significant associations for all-cause dementia, vascular dementia, or frontotemporal dementia. The study authors emphasized that the work is observational and does not prove that menopause-related protein changes directly cause dementia, noting that most women do not develop the condition following menopause.